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Linkage and association studies have recently implicated dystrobrevin-binding protein 1 (DTNBP1) in the etiology
of schizophrenia. We analyzed seven previously tested DTNBP1 single-nucleotide polymorphisms (SNPs) in a cohort
of 524 individuals with schizophrenia or schizoaffective disorder and 573 control subjects. The minor alleles of
three SNPs (P1578, P1763, and P1765) were positively associated with the diagnosis of schizophrenia or schi-
zoaffective disorder in the white subset of the study cohort (258 cases, 467 controls), with P1578 showing the
most signiﬁcant association (odds ratio 1.76, P p .0026). The same three SNPs were also associated in a smaller
Hispanic subset (51 cases, 32 controls). No association was observed in the African American subset (215 cases,
74 controls). A stratiﬁed analysis of the white and Hispanic subsets showed association with the minor alleles of
four SNPs (P1578, P1763, P1320, and P1765). Again, the most signiﬁcant association was observed for P1578 (P
p .0006). Haplotype analysis supported these ﬁndings, with a single risk haplotype signiﬁcantly overrepresented
in the white sample (P p .005). Our study provides further evidence for a role of the DTNBP1 gene in the genetic
etiology of schizophrenia.
Schizophrenia (MIM #181500) is a common, complex
disorder affecting ∼1% of the population worldwide. Its
high heritability (∼80%) and elevated sibling recurrence
risk ( ) indicate a strong genetic component (Mc-l ≈ 10S
Gufﬁn et al. 1995; Cardno and Gottesman 2000; Lev-
inson and Mowry 2000). Current data suggest that sev-
eral loci with low individual effects contribute to the
genetic risk (Risch 1990). The identiﬁcation of suscepti-
bility genes for common, complex disorders is challeng-
ing, since large numbers of well-diagnosed cases are
needed to detect weak effects of individual susceptibility
genes (e.g., Altshuler et al. 2000; reviewed byRisch2000).
An added obstacle in the study of the genetic basis of
psychiatric disorders like schizophrenia is the lack of ob-
jective biomarkers to aid in determination of phenotypes.
Genomewide scans can be used to pinpoint the chro-
mosomal location of susceptibility genes. However, be-
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cause of the low marker resolution, the linked intervals
are large—requiring additional approaches, such as link-
age disequilibrium (LD) mapping, to identify disease-as-
sociated genes under linkage peaks.
Despite the difﬁculties in standardizing phenotypic in-
formation, genomewide scans have now reliably impli-
cated several loci in the etiology of schizophrenia, in-
cluding a region on chromosome 6p (6p24-22) (Lewis et
al. [2003] and references within). Straub et al. (2002)
subsequently narrowed the interval on chromosome 6p
by using LD mapping to analyze a sample of 270 Irish
pedigrees who were multiply affected with schizophrenia,
ﬁnding signiﬁcant association of several variants in the
DTNBP1 gene on chromosome 6p22.3. Reanalysis of
these data identiﬁed a haplotype block, which spanned
30 kb and contained a single high-risk haplotype of rel-
atively recent evolutionary origin (van den Oord et al.
2003). Several replication studies in different populations
have been reported since then, and most have conﬁrmed
an associationwithDTNBP1 (Morris et al. 2003; Schwab
et al. 2003; Tang et al. 2003; Van Den Bogaert et al.
2003; Kirov et al. 2004; Williams et al. 2004). However,
despite the overall conﬁrmation of an association with
DTNBP1, there was considerable heterogeneity among
the associated alleles and haplotypes, suggesting allelic
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heterogeneity at this locus. The majority of studies have
employed a family-based approach (Straub et al. 2002;
Schwab et al. 2003; Tang et al. 2003; van den Oord et
al. 2003; Kirov et al. 2004). VanDen Bogaert et al. (2003),
who observed increased signiﬁcance in positive-family-
history cases in a Swedish case-control sample, hypoth-
esized that DTNBP1 is particularly involved in the eti-
ology of schizophrenia in cases with familial loading.
DTNBP1 is an evolutionarily conserved protein, which
binds a- and b-dystrobrevin—components of the dystro-
phin-associated protein complex (DPC) in muscle and
brain (Benson et al. 2001). In muscle, DTNBP1 colocal-
izes with a-dystrobrevin at the sarcolemma, and disrup-
tion of the DPC results in Duchenne and Becker muscular
dystrophies (DMD and BMD) (Straub and Campbell
1997; Muntoni et al. 2003). It is interesting that DMD
and schizophrenia share a number of phenotypes: both
disorders have neurological ﬁndings, including ocular-
control abnormalities characteristic of cerebellar prob-
lems (Lui et al. 2001; Anderson et al. 2002; Avila et al.
2002). Furthermore, recent research has highlighted the
presence of cognitive impairments in DMD and BMD,
which may relate to the now well-established cognitive
deﬁcits observed in schizophrenia (North et al. 1996;Hin-
ton et al. 2000; reviewed byMehler 2000). These ﬁndings
suggest that the DPC may be involved in the etiology
of both muscular dystrophy and schizophrenia. How-
ever, Talbot et al. (2004) recently reported presynaptic
DTNBP1 reductions at hippocampal formation sites in
patients with schizophrenia. These sites lack neuronal dys-
trobrevin, indicating that the role of DTNBP1 in schizo-
phrenia may be independent of the DPC. In addition,
Talbot et al. (2004) showed that the same patients with
schizophrenia exhibited an increase in vesicular glutamate
transporter 1 (VGluT-1), providing evidence of a potential
role of DTNBP1 in glutamate neurotransmission, which
has been implicated in the pathogenesis of schizophrenia
(Collier and Li 2003).
Despite intensive resequencing efforts, no DTNBP1
coding variants have yet been identiﬁed (dbSNP build
120 [see dbSNP Home Page]) (Williams et al. 2004).
Bray et al. (2003), however, have recently detected strong
allele-speciﬁc expression of the DTNBP1 gene in the
brain, raising the possibility that cis-acting variationmay
contribute to the role of DTNBP1 in the etiology of
schizophrenia.
We present here an independent replication of the as-
sociation of theDTNBP1 locus with schizophrenia. This
is the ﬁrst report of a positive association in a U.S. sample
and the ﬁrst study examining DTNBP1 variants in an
African American population. Our sample consisted of
524 cases (patients with a diagnosis of either schizophre-
nia [ ] or schizoaffective disorder [ ]) andnp 421 np 103
573 controls of various ethnicities.
Cases were recruited from the inpatient and outpatient
clinical services of the Zucker Hillside Hospital, a di-
vision of the North Shore–Long Island Jewish Health
System, where patients are screened for potential re-
cruitment into research studies by the Clinical Assess-
ment and Training (CAT) unit of the National Institutes
of Health–funded Hillside Hospital Intervention Re-
search Center. The CAT unit monitors the inpatient and
outpatient hospital census daily and conducts prelimi-
nary screening and recruitment functions. Inclusion cri-
teria for screening for this study included a clinical di-
agnosis of a psychotic disorder, no active substance
abuse, and the ability to provide informed consent. After
providing written informed consent, each subject was
assessed with the Structured Clinical Interview for DSM-
IV Axis I disorders (SCID, version 2.0), which was ad-
ministered by trained raters. Standardized diagnostic as-
sessments were supplemented with clinical information
obtained by a review of medical records and interviews
with family informants when possible, and all diagnostic
information was compiled into a narrative case sum-
mary. Information on the onset and course of Axis I
illness, the presence of Axis II pathology, the presence
of Axis III diagnoses, and a brief description of the sub-
ject’s psychosocial and occupational functioning during
the course of illness was presented to a consensus di-
agnostic committee that consisted of a minimum of three
senior faculty with DSM-IV diagnostic experience, as
well as other faculty and trainees with SCID experience.
All available information was used to arrive at a con-
sensus DSM-IV diagnosis.
Healthy controls were recruited by the ZuckerHillside
Hospital Normal Control Program and were ascertained
in the same manner as the cases. Potential participants
were recruited by use of local newspaper advertisements,
ﬂyers, and community Internet resources and underwent
initial telephone screening to assess eligibility criteria.
The nonpatient SCID (SCID-NP) was administered to
subjects who met eligibility criteria, to rule out the pres-
ence of an Axis I psychiatric disorder; a urine toxicology
screen for drug use and an assessment of the subject’s
family history of psychiatric disorders were also per-
formed. Exclusion criteria included (current or past)
Axis I psychiatric disorder, psychotropic drug treatment,
substance abuse, a ﬁrst-degree family member with an
Axis I psychiatric disorder, or the inability to provide
written informed consent. A subset of the control cohort
was collected through the Massachusetts General Hos-
pital Clinical Research Program, in conjunction with the
Harvard Medical School–Partners Center for Genetics
and Genomics in Boston. This subset comprised disease-
free subjects 118 years of age. For the purposes of the
study, “disease” was deﬁned as current or past diagnoses
made by a medical-care provider that required medi-
cation or other forms of treatment or therapy. Surgery
was considered to be an exclusionary criterion, with the
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Figure 1 Comparison of DTNBP1 associations. The DTNBP1 gene is shown in the upper part of the ﬁgure (GenBank accession number
NM_183041; variant 3). Exons are represented by boxes, and the SNPs described by Straub et al. (2002) are indicated below. Associated alleles
and haplotypes, as reported elsewhere, are summarized in the lower part of the ﬁgure. Signiﬁcant associations are indicated by the respective
alleles. Two hyphens (“--”) represent a tested but nonsigniﬁcant marker. Single risk haplotypes are shaded. Complex haplotype patterns (such
as those described by Straub et al. [2002] and Kirov et al. [2004]) or haplotypes including a signiﬁcant number of novel SNPs (Williams et al.
2004) were omitted but are discussed in the text.
exception of orthopedic procedures, appendectomy, or
surgeries that were related to trauma. Subjects who took
prescription medications or regularly used over-the-
counter medications were also excluded. Eligible subjects
completed a structured family and medical questionnaire
that detailed current and past history of psychiatric illness
and pharmacological or psychotherapeutic psychiatric
treatment. All responses to the self-report form were con-
ﬁrmed by physicians in clinical interviews with subjects.
Physical exams were completed at the study visit. This
study was approved by the institutional review boards of
the North Shore–Long Island Jewish Health System and
Harvard Medical School–Partners Center for Genetics
and Genomics. The largest ethnic groups represented in
the study were whites (258 cases [mean age 39.4 years;
35.7% female/64.3% male] and 467 controls [mean age
39.3 years; 51.8% female/48.2% male]), African Amer-
icans (215 cases [mean age 35.9 years; 36.3% female/
63.7% male] and 74 controls [mean age 31.9 years;
59.5% female/40.5% male]), and Hispanics (51 cases
[mean age 34.2 years; 35.3% female/64.7% male] and
32 controls [mean age 32.9 years; 40.6% female/59.4%
male]).
We genotyped seven of the SNPs that were initially
described by Straub et al. (2002). They included P1635,
which had yielded the most signiﬁcant results in the study
by Straub et al. (2002); P1320, whichwasmost signiﬁcant
in the studies by van den Oord et al. (2003) and Schwab
et al. (2003); and the haplotype-tag SNPs P1578, P1763,
and P1765, which were described by van den Oord et al.
(2003). All SNPs are listed in table 1. Genotyping was
performed by MALDI-ToF mass spectrometry by use of
the Sequenom system. Tests of Hardy-Weinberg equilib-
rium (HWE) were performed at each SNP locus (Hill
1974). P1635 was the only SNP that was out of HWE
across several ethnic groups in cases and controls andwas
therefore excluded from all analyses.
Statistical inference for single-SNP associations was
based on x2 test statistics. For each SNP, an allelic as-
sociation test and the Cochran-Armitage trend test (test
for additive allelic effects) were performed (Sasieni
1997). Odds ratios (ORs) associated with the minor al-
lele were also produced for each SNP. To reduce the
potential inﬂuence of population stratiﬁcation, the x2
tests were computed separately for each of the three
largest ethnic groups: whites, African Americans, and
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Table 1
Allele Frequencies and P Values for Six DTNBP1 SNP Markers
SUBSET
AND SNP ID
(dbSNP NUMBER)
ALLELES
(MAJOR/
MINOR)
PATIENTS WITH SCHIZOPHRENIA
OR SCHIZOAFFECTIVE DISORDER PATIENTS WITH SCHIZOPHRENIA
Minor-Allele
Frequency
Allele
P
Trend
P OR
Minor-Allele
Frequency
Allele
P
Trend
P ORControlsa Casesb Controlsa Casesc
White:
P1583 (rs909706) C/T .342 .346 .8795 .8801 1.02 .342 .349 .8051 .8046 1.03
P1578 (rs1018381) C/T .073 .121 .0026 .0037 1.76 .073 .113 .0194 .0213 1.62
P1763 (rs2619522) A/C .156 .207 .0169 .0195 1.41 .156 .213 .0146 .0161 1.47
P1320 (rs760761) C/T .163 .197 .1194 .1276 1.26 .163 .207 .0649 .0676 1.34
P1765 (rs2691528) G/A .157 .208 .0171 .0195 1.41 .157 .213 .0162 .0176 1.46
P1325 (rs1011313) C/T .070 .060 .4733 .4786 .85 .070 .058 .4380 .4397 .82
Hispanic:
P1583 (rs909706) C/T .345 .330 .8491 .8496 .94 .345 .325 .8073 .8150 .91
P1578 (rs1018381) C/T .060 .177 .0506 .0449 3.36 .060 .171 .0654 .0460 3.23
P1763 (rs2619522) A/C .154 .324 .0243 .0319 2.63 .154 .305 .0480 .0565 2.41
P1320 (rs760761) C/T .150 .300 .0351 .0540 2.43 .150 .278 .0775 .1012 2.18
P1765 (rs2691528) G/A .150 .320 .0171 .0239 2.67 .150 .300 .0385 .0473 2.43
P1325 (rs1011313) C/T .117 .080 .4411 .4802 .66 .117 .088 .5692 .6043 .73
African American:
P1583 (rs909706) C/T .221 .234 .7518 .7567 1.08 .221 .236 .72692 .73135 1.09
P1578 (rs1018381) C/T .317 .301 .7210 .7270 .93 .317 .301 .72910 .73492 .93
P1763 (rs2619522) A/C .390 .357 .4949 .5043 .87 .390 .356 .49307 .50293 .87
P1320 (rs760761) C/T .345 .349 .9286 .9324 1.02 .345 .358 .78009 .79132 1.06
P1765 (rs2691528) G/A .371 .358 .7715 .7737 .94 .371 .358 .78441 .78663 .95
P1325 (rs1011313) C/T .043 .058 .4819 .4842 1.38 .043 .057 .51561 .52014 1.36
NOTE.—Signiﬁcant P values are shown in bold, underlined italics. P values that approach signiﬁcance are shown in bold italics.
a Sample sizes were as follows: white ( ), Hispanic ( ), African American ( ).np 467 np 32 np 74
b Sample sizes were as follows: white ( ), Hispanic ( ), African American ( ).np 258 np 51 np 215
c Sample sizes were as follows: white ( ), Hispanic ( ), African American ( ).np 196 np 41 np 184
Hispanics. A stratiﬁed Cochran-Armitage trend test was
used in the analysis of association across ethnic groups.
Haplotype associations were explored using score tests
that account for linkage phase ambiguity (Schaid et al.
2002; Lake et al. 2003). The score tests, derived from
generalized linear models, are used for global tests of
association, as well as haplotype-speciﬁc tests. In addi-
tion, a permutation algorithm was applied in the testing
framework to ﬁnd the maximum of the haplotype-spe-
ciﬁc score statistics and the associated P value for this
maximum. The Haplo Stats program, which implements
the methods of Schaid et al. (2002), was used for these
analyses. Haplotypes were imputed, and frequencies
were estimated using the estimation facility in Haplo
Stats, which is based on the expectation-maximization
algorithm.
The results of the single-SNP analyses are presented in
table 1. The minor alleles of three SNPs (P1578, P1763,
and P1765) were positively associated with the diagnosis
of schizophrenia or schizoaffective disorder in the white
subset. The most signiﬁcant P value was observed for
P1578 (OR 1.76; allele test ; trend testPp .0026 Pp
). All three SNPs remained signiﬁcant when the.0037
analysis was restricted to patients with schizophrenia
( ), and a fourth SNP, P1320, approached signif-np 196
icance (OR 1.34; allele test ; trend testPp .0649 Pp
). For the four associated SNPs, the observed as-.0676
sociations occurred with the minor allele. Therefore, on
the single-SNP level, our results agree with those obtained
by Straub et al. (2002) and van den Oord et al. (2003),
with the exception of P1578 (which did not reach sig-
niﬁcance in their analyses). Despite the small sample size,
the same SNPs were associated in the Hispanic subgroup,
but with higher estimated ORs. For example, P1578 was
positively associated with the diagnosis of schizophrenia
or schizoaffective disorder in the Hispanic subset (OR
3.36; allele test ; trend test ). WhenPp .0506 Pp .0449
restricted to patients with schizophrenia, only P1763 and
P1765 remained signiﬁcant in the Hispanic cohort, which
is likely due to the small sample size, as the estimated
ORs suggest. When the data from the white and Hispanic
subsets were analyzed jointly with a stratiﬁed Cochran-
Armitage trend test, the results were more pronounced
(see table 2). It is interesting that no association of the
above SNPs was observed in the AfricanAmerican sample
(215 cases, 74 controls), and the estimated ORs did not
indicate any trend of association.
Although recent case-control studies have reported
DTNBP1 associations with schizophrenia (Kirov et al.
2004; Williams et al. 2004), a previous study raised the
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Table 2
Combined Analysis of Whites and Hispanics
with Schizophrenia or Schizoaffective Disorder
SNP
Alleles
(Major/Minor) Test Statistic P
P1583 C/T .0814 .9352
P1578 C/T 3.4141 .0006
P1763 A/C 2.9569 .0031
P1320 C/T 2.1394 .0324
P1765 G/A 3.0123 .0026
P1325 C/T .9298 .3525
NOTE.—Signiﬁcant P values are shown in bold,
underlined italics.
Table 3
LD (D′) at the DTNBP1 Locus
SUBSET
AND SNP
LD (D′) FOR SNPS
P1583 P1578 P1763 P1320 P1765
White:
P1578 .93 … … … …
P1763 .96 1.00 … … …
P1320 .87 .96 .97 … …
P1765 .94 1.00 1.00 .97 …
P1325 .97 .78 1.00 .56 .94
Hispanic:
P1578 .84 … … … …
P1763 .94 .99 … … …
P1320 1.00 .81 1.00 … …
P1765 1.00 .99 1.00 1.00 …
P1325 1.00 .23 1.00 1.00 1.00
African American:
P1578 1.00 … … … …
P1763 1.00 1.00 … … …
P1320 1.00 .85 .99 … …
P1765 1.00 .99 1.00 .97 …
P1325 .91 1.00 1.00 1.00 .96
possibility that DTNBP1 variation may be particularly
involved in familial cases of schizophrenia (Van Den Bo-
gaert et al. 2003). When we restricted our analysis to
those cases with a positive family history (whites: np
), none of the SNPs remained signiﬁcant (data not58
shown); however, this should be interpreted with cau-
tion, since the sample size is very small.
LD between the selected SNPs we tested was assessed
by use of Lewontin’s D′ statistic. We observed high LD
from P1583 to P1765 in all ethnic groups (see table 3).
This 11-kb interval generally showed very high LD in
previous studies. In the white group, the marker pair
P1325-P1320 showed the lowest D′ value, as was the
case in the samples used in the studies by Straub et al.
(2002) and Schwab et al. (2003). In the Hispanic group,
the lowest D′ values were observed for marker pairs
involving P1578 (P1325-P1578 and P1320-P1578).
Similarly, van den Oord et al. (2003) found that marker
pairs involving P1578 showed considerably lower LD
than other marker pairs.
In whites, Hispanics, and African Americans, ﬁve hap-
lotypes had estimated frequencies 10.025 and were in-
cluded in the association testing. Together, these haplo-
types accounted for 94%–98% of all haplotypes (table
4). One haplotype consisted of the rare (minor) allele for
SNPs P1578, P1763, P1320, and P1765, and the common
(major) allele for P1325 and P1583 was overrepresented
in the white and Hispanic groups. However, signiﬁcance
was reached only in the white population (haplotype-
speciﬁc ; maximum haplotype-speciﬁcPp .005 Pp
). The overrepresentation of the C-T-C-T-A-C hap-.024
lotype in whites and Hispanics is consistent with the as-
sociations of the rare alleles for markers P1578, P1763,
P1320, and P1765 on the single-SNP level and with the
high LDwe observed in this interval. In the AfricanAmer-
ican group, this haplotype was present at almost equal
frequencies in cases and controls, consistent with the neg-
ative associations on the single-SNP level. It is worth not-
ing that P1578, which reached the most signiﬁcant P val-
ues in the single-SNP analyses, is also the only SNP with
the associated (minor) allele observed solely on the over-
represented haplotype. Our markers included two sets
of haplotype-tag SNPs described by van den Oord et al.
(2003) (P1578-P1763 and P1578-P1765). However, our
risk haplotype differed from the one reported by this
group, suggesting that these tag SNPs may not be gen-
erally applicable across different populations. Van den
Oord et al. (2003) deﬁned a haplotype block (P1792–
P1635), in which a limited number of haplotypes ac-
counted for the majority of all observed haplotypes. Since
our data show high LD extending from P1765 to P1583
(the 5′-most marker we genotyped), we could not examine
this feature in our sample.
Figure 1 summarizes our ﬁndings in relation to pre-
viously reported associations for the DTNBP1 locus.
Comparisons were restricted to the initial SNP set de-
scribed by Straub et al. (2002). A growing number of
studies, including ours, have now reported association
of several DTNPB1 SNPs with schizophrenia. However,
a precise comparison is hampered by the fact that the
SNP sets overlapped but were not identical. Overall,
there is considerable disagreement both within studies
(differences between single-SNP associations and alleles
present on associated haplotypes) and between studies.
As described above, the samples in our study showed
signiﬁcant association with the minor alleles (T-C-T-A)
for P1578, P1763, P1320, and P1765 in two different
ethnic groups, and a single risk haplotype, which in-
cludes the same rare alleles plus the common alleles for
P1325 and P1583, emerged in the white cohort. Five of
these SNPs are present on the risk haplotype identiﬁed
by van den Oord et al. (2003), and, for four of them,
our risk haplotype contains the same alleles as the hap-
lotype described by van den Oord et al. (2003).
The only exception is P1578, for which our haplotype
contained the rare allele (which we also found to be sig-
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Table 4
DTNBP1 Haplotypes
SUBSET
HAPLOTYPES FREQUENCY IN
HAPLOTYPE-
SPECIFIC PP1583 (C/T)a P1578 (C/T)a P1763 (A/C)a P1320 (C/T)a P1765 (G/A)a P1325 (C/T)a Casesb,c Controlsd
White:
C C A C G C .4505 .4999 .0793
T C A C G T .0578 .0648 .6027
T C A C G C .2817 .2662 .5587
C C C T A C .0816 .0818 .9468
C T C T A C .1174 .0714 .005
Hispanic:
C C A C G C .3482 .4946 .0959
T C A C G T .0787 .1167 .4188
T C A C G C .2496 .2217 .7146
C C C T A C .1471 .0750 .2095
C T C T A C .1471 .0750 .1602
African American:
C C A C G C .3884 .4444 .5444
T C A C G T .0513 .0158 .8075
T C A C G C .1788 .1699 .7573
C C C T A C .0810 .0617 .4308
C T C T A C .2630 .2525 .9304
NOTE.—The signiﬁcant P value is shown in bold, underlined italics.
a Major allele/minor allele.
b Individuals with a diagnosis of schizophrenia or schizoaffective disorder.
c Total frequency in cases: .9891 (whites), .9706 (Hispanics), .9624 (African Americans).
d Total frequency in controls: .9841 (whites), .9830 (Hispanics), .9443 (African Americans).
niﬁcantly associated on the single-SNP level but which
did not show signiﬁcant P values in the study by van den
Oord et al. [2003]). Of interest, van denOord et al. (2003)
saw considerably lower LD with marker pairs involving
P1578 than with most other pairs. It is conceivable that
the haplotype we detected in our population is evolu-
tionarily related to the haplotype described by van den
Oord et al. (2003), as seems to be true for the risk hap-
lotype identiﬁed in a Swedish population by Van Den
Bogaert et al. (2003). In their sample, three of the ﬁve
alleles present on the haplotype are identical to the ones
on the haplotype identiﬁed by van den Oord et al. (2003).
Again, P1578 is different, and, like our haplotype, it con-
tains the rare allele (T). Schwab et al. (2003) observed
positive associations for ﬁve of the SNPs described by
Straub et al. (2002), however, with the common allele for
each marker. Consistent with these results, one haplotype,
consisting of the common allele for each SNP, was over-
transmitted in their samples. Finally, the two most recent
studies included a substantial number of novel SNPs, in
addition to several of the SNPs described by Straub et al.
(2002): Kirov et al. (2004) observed positive associations
with the common allele for two of the SNPs (P1635 and
P1757) described by Straub et al. (2002), but they were
unable to assign a single risk haplotype, because of the
large number of signiﬁcant two-, three-, and four-marker
haplotypes. Williams et al. (2004) genotyped four of the
SNPs described by Straub et al. (2002) but found no as-
sociation on the single-SNP or haplotype level. A highly
signiﬁcant haplotype was observed only after adding
novel SNPs (Williams et al. 2004).
In summary, there is now little doubt that theDTNBP1
gene plays a signiﬁcant role in the genetic etiology of
schizophrenia, since eight studies (including ours) have
reported signiﬁcant associations with the same markers,
all located in the 5′ portion of the gene. To our knowledge,
this is the ﬁrst study examining DTNBP1 variants in dif-
ferent U.S. populations. It is also the ﬁrst study analyzing
DTNBP1 variants in an African American population.
We observed positive associations of DTNBP1 variants
in both the white and Hispanic groups. No signiﬁcant
associations were observed in the African American pop-
ulation, which is most likely due to an insufﬁcient sample
size, as suggested by the ORs (table 1). It is possible that
DTNBP1 may not contribute to schizophrenia in this
ethnic group or that its contribution may be signiﬁcantly
smaller than in other populations.
We are aware of the potential danger of spurious re-
sults caused by hidden population substructure.Although
this is a possible limitation of our study, empirical data
obtained from European American, African American,
and European populations suggest that carefully matched
studies of moderate size are unlikely to contain stratiﬁ-
cation levels leading to false-positive associations (Ardlie
et al. 2002; Pankow et al. 2002). A second possible lim-
itation of our study is that, overall, our sample showed
a sex imbalance. However, there is currently no evidence
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suggesting a sexually dimorphic effect of the DTNBP1
gene on the development of schizophrenia.
We observed an overrepresentation of the same hap-
lotype in two ethnic groups, suggesting that the disease-
causing variant may be identical in the Hispanic and
white populations in our study. However, a comparison
of the reported studies so far does not support a single
disease-associated variant at the DTNBP1 locus, since
association has been found with different haplotypes. It
is therefore possible that the contribution of DTNBP1
to schizophrenia is deﬁned by several susceptibility al-
leles that have arisen on different haplotypes.
A review of the disease-causing variants identiﬁed to
date shows that most represent missense or nonsense
mutations that affect the coding region (Botstein and
Risch 2003). However, no DTNBP1 coding variants
have yet been identiﬁed, and it is therefore possible that
the functional variant(s) are not located within the pro-
tein-coding portion of the gene. A recent study has re-
ported allelic differences in DTNBP1 expression in the
brain, suggesting that regulatory variant(s) inﬂuence
DTNBP1 expression levels (Bray et al. 2003). In this
context, it is important to note that Williams et al.
(2004) observed the strongest evidence of association for
a haplotype that contained a putative regulatory SNP.
A thorough analysis of the complete variation of the
DTNBP1 locus, including all regulatory elements across
multiple populations, will be needed to dissect the con-
tribution of the functional variant(s) of the DTNBP1
gene to schizophrenia.
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